Qim­ing, Hill­house bet on Ja­co­bio's nascent pipeline of first-in-class drug hope­fuls in $55M round

Qim­ing Cap­i­tal and Hill­house Cap­i­tal are bet­ting on a Chi­nese biotech to de­liv­er world-class in­no­va­tion in their lat­est in­vest­ment.

Aside from the two promi­nent VCs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.